{"id":231120,"date":"2026-02-11T14:23:17","date_gmt":"2026-02-11T20:23:17","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/02\/abstract-osimertinib-osi-is-first-line-treatment-for-metastatic-lung-adenocarcinoma-with-egfr-mutations"},"modified":"2026-02-11T14:23:17","modified_gmt":"2026-02-11T20:23:17","slug":"abstract-osimertinib-osi-is-first-line-treatment-for-metastatic-lung-adenocarcinoma-with-egfr-mutations","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/02\/abstract-osimertinib-osi-is-first-line-treatment-for-metastatic-lung-adenocarcinoma-with-egfr-mutations","title":{"rendered":"Abstract: Osimertinib (Osi) is first-line treatment for metastatic lung adenocarcinoma with EGFR mutations"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/abstract66.jpg\"><\/a><\/p>\n<p>Here, Jonathan M. Kurie &amp; team show Osi-resistant cancer secrete effector proteins that increase the metastatic properties of drug-naive cells and influence lung cancer progression through paracrine mechanisms:<\/p>\n<p>The figure shows Osi-resistant (OR) cells show Golgi remodeling compared with drug-na\u00efve (DN) cells.<\/p>\n<hr>\n<p>\n<sup>1<\/sup>Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas\u2013MD Anderson Cancer Center, Houston, Texas, USA.<\/p>\n<p><sup>2<\/sup>Section of Hematology and Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.<\/p>\n<p><sup>3<\/sup>Tulane Cancer Center, Louisiana <i>Cancer Res<\/i>earch Center, New Orleans, Louisiana, USA.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here, Jonathan M. Kurie &amp; team show Osi-resistant cancer secrete effector proteins that increase the metastatic properties of drug-naive cells and influence lung cancer progression through paracrine mechanisms: The figure shows Osi-resistant (OR) cells show Golgi remodeling compared with drug-na\u00efve (DN) cells. 1Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas\u2013MD Anderson Cancer [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-231120","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=231120"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231120\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=231120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=231120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=231120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}